For an adult with established atherosclerotic cardiovascular disease, especially after an acute coronary syndrome and LDL ≥70 mg/dL despite high‑intensity statin therapy, what does the IMPROVE‑IT trial demonstrate about the efficacy and safety of adding ezetimibe 10 mg daily to the statin regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IMPROVE-IT Trial: Role and Effects in LDL Management After Acute Coronary Syndrome

Adding ezetimibe 10 mg daily to simvastatin 40 mg in adults with recent acute coronary syndrome (within 10 days) and LDL ≥70 mg/dL significantly reduces major adverse cardiovascular events by 6.4% relative risk (2.0% absolute risk reduction) over 6 years, with enhanced benefit in patients with diabetes mellitus (5.5% absolute reduction) and other high-risk features. 1

Core Trial Design and Population

The IMPROVE-IT trial enrolled 18,144 patients over age 50 who were hospitalized for acute coronary syndrome within the preceding 10 days, with median time from ACS to randomization of 5 days. 1 Patients were randomized to either ezetimibe 10 mg plus simvastatin 40 mg versus placebo plus simvastatin 40 mg, with median follow-up of 6 years. 1

Baseline LDL-C requirements:

  • 50-100 mg/dL (1.3-2.6 mmol/L) for patients already on lipid-lowering therapy
  • 50-125 mg/dL (1.3-3.2 mmol/L) for patients not on lipid-lowering therapy
  • Mean baseline LDL-C was 93.8 mg/dL in both groups 1

LDL-C Reduction Achieved

Ezetimibe produced substantial additional LDL-C lowering beyond moderate-intensity statin:

  • At 1 year: 24% greater LDL-C reduction with ezetimibe versus placebo 1
  • Absolute LDL-C reduction: 16.7 mg/dL compared to placebo 2
  • Achieved on-treatment LDL-C: 53.2 mg/dL with ezetimibe versus 69.9 mg/dL with placebo 1

This demonstrates that ezetimibe blocks intestinal cholesterol absorption via the Niemann-Pick C1-like 1 protein, typically reducing LDL-C by 15-25% when added to statin therapy. 1, 3

Cardiovascular Outcomes: Primary Endpoint

The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization ≥30 days post-randomization, or nonfatal stroke) was significantly reduced:

  • Hazard ratio: 0.936 (95% CI 0.887-0.996, p=0.016) 1, 4
  • 7-year Kaplan-Meier event rate difference: 2.0% absolute reduction 4, 2
  • Relative risk reduction: 6.4% 1

The benefit appeared early after ACS and persisted throughout the 6-year follow-up period. 1

Enhanced Benefit in High-Risk Subgroups

Patients with Diabetes Mellitus

Diabetes patients derived substantially greater benefit than those without diabetes:

  • 7-year absolute risk reduction: 5.5% in diabetes patients (40.0% vs 45.5%; HR 0.85,95% CI 0.78-0.94) 1, 5
  • Compared to only 0.7% absolute reduction in non-diabetic patients (HR 0.98,95% CI 0.91-1.04) 5
  • P-interaction = 0.02, indicating statistically significant differential benefit 5

Component reductions in diabetes patients:

  • Myocardial infarction: 24% relative reduction 5
  • Ischemic stroke: 39% relative reduction 5

The 4,933 diabetes patients (27% of trial) were older, more often female, had more prior MI and revascularization, and presented more frequently with NSTEMI compared to non-diabetic patients. 5

Elderly Patients (≥75 Years)

Patients ≥75 years experienced a 20% relative reduction in the primary endpoint regardless of diabetes status (P-interaction = 0.91), demonstrating consistent benefit in this vulnerable population. 5, 2

High TIMI Risk Score Patients

Risk stratification revealed important patterns:

  • All diabetes patients benefited from ezetimibe regardless of TIMI risk score 5
  • Among non-diabetic patients, only those with high TIMI risk scores experienced significant benefit (18% relative reduction in CV death/MI/ischemic stroke) 5
  • Low or moderate risk non-diabetic patients showed no benefit (P-interaction = 0.034) 5

Other High-Risk Subgroups with Benefit

The following prespecified subgroups showed similar or greater benefit compared to their non-high-risk counterparts: 2

  • Prior coronary artery bypass graft
  • History of stroke
  • Polyvascular disease
  • Low baseline LDL-C
  • Renal dysfunction
  • Prior heart failure

Safety Profile

Ezetimibe demonstrated excellent safety when added to simvastatin:

  • No clear imbalances in adverse events compared with placebo 1
  • Safety events were similar between ezetimibe and placebo across all high-risk subgroups 2
  • No safety concerns from achieving very low LDL-C concentrations (median 53.2 mg/dL) 1
  • Well-tolerated over the entire 6-year follow-up period 1, 6

Quality Assessment and Study Limitations

The trial had mild deficiencies in the relevance category due to 19% failure to complete follow-up, but overall performed well according to the Cochrane Risk of Bias Assessment Tool. 1 The study was adequately powered, double-blinded, and had appropriate randomization procedures. 1

Current Guideline Recommendations Based on IMPROVE-IT

Class 1 Recommendations (Should Be Done)

For patients with ACS and LDL-C ≥70 mg/dL on maximally tolerated statin therapy, adding a nonstatin lipid-lowering agent (including ezetimibe) is recommended to reduce MACE. 1

Class 2a Recommendations (Reasonable to Do)

For patients with ACS already on maximally tolerated statin with LDL-C 55-69 mg/dL, adding ezetimibe is reasonable to further reduce MACE risk. 1

Class 2b Recommendations (May Be Considered)

Concurrent initiation of ezetimibe in combination with maximally tolerated statin at the time of ACS hospitalization may be considered to reduce MACE. 1

Practical Clinical Algorithm

For adults with established ASCVD after ACS:

  1. If not on statin or on low/moderate-intensity statin: Initiate high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 1

  2. Reassess lipid profile 4-8 weeks after discharge: 1

  3. If LDL-C ≥70 mg/dL on maximally tolerated statin:

    • Add ezetimibe 10 mg daily (Class 1 recommendation) 1
    • Expected additional LDL-C reduction: 15-25% 1, 3
    • Target achieved LDL-C: <55 mg/dL 1

  4. If LDL-C 55-69 mg/dL on maximally tolerated statin:

    • Adding ezetimibe is reasonable, particularly in high-risk patients (diabetes, elderly, high TIMI score, polyvascular disease) 1, 5

  5. If LDL-C remains ≥70 mg/dL despite statin plus ezetimibe:

    • Add PCSK9 inhibitor (evolocumab or alirocumab) for additional 50-60% LDL-C reduction 1, 3

Common Pitfalls and Caveats

Do not de-escalate high-intensity statin therapy in patients tolerating treatment, even when very low LDL-C levels are achieved. No safety concerns have been observed with LDL-C levels as low as 53 mg/dL. 1

Do not delay ezetimibe addition in diabetes patients with ACS and LDL ≥70 mg/dL on statin. This population derives the greatest absolute benefit (5.5% absolute risk reduction over 7 years). 1, 5

Do not assume all non-diabetic patients benefit equally. Among non-diabetic patients, those at low or moderate risk by TIMI score showed no benefit from ezetimibe addition, whereas high-risk patients experienced significant benefit. 5

Recognize that IMPROVE-IT used moderate-intensity statin (simvastatin 40 mg), not high-intensity statin. Current guidelines recommend initiating high-intensity statin first in ACS patients, then adding ezetimibe if LDL-C goals are not met. 1

The benefit of ezetimibe is commensurate with its LDL-C lowering effect (approximately 7% event reduction for 17 mg/dL LDL-C reduction). This aligns with the principle that "lower is better" for LDL-C in very high-risk patients, regardless of the mechanism used to achieve lowering. 4, 6

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Treatment of Hyperlipidemia with Ezetimibe and Statins

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the Statin (HMG-CoA reductase inhibitor) plus Ezetimibe trial?
What are alternative medications for hyperlipidemia (high cholesterol) if a patient is unable to tolerate statins (HMG-CoA reductase inhibitors)?
What are the alternatives to statins (HMG-CoA reductase inhibitors) for decreasing low-density lipoprotein (LDL) levels?
What are the alternatives to statins (HMG-CoA reductase inhibitors) for decreasing low-density lipoprotein (LDL) cholesterol?
What are alternative medications to statins (HMG-CoA reductase inhibitors) for patients who cannot tolerate them?
What is the recommended adult dosing regimen for linezolid, including dose, route, treatment duration, renal or hepatic adjustments, and monitoring for drug interactions?
Why are acute coronary syndrome (ACS) rates continuing to rise despite evidence that statin therapy reduces cardiovascular events?
What are the recommended milrinone dosing regimen (including loading dose and continuous infusion), renal dose adjustment, contraindications, required monitoring (blood pressure, cardiac rhythm, electrolytes, platelet count), and alternative therapies for patients with acute decompensated heart failure or cardiogenic shock?
What is the appropriate management for a patient with an LDL‑C level of 178 mg/dL?
Can propranolol be prescribed for a patient with interstitial lung disease and essential tremor?
Can an adult with chronic stable angina who is already using sublingual or transdermal nitroglycerin for acute episodes safely add nicorandil (oral) as a long‑term anti‑anginal therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question